TransCode Therapeutics
RNAZ
7 hedge funds and large institutions have $186K invested in TransCode Therapeutics in 2024 Q3 according to their latest regulatory filings, with 1 funds opening new positions, 4 increasing their positions, 1 reducing their positions, and 6 closing their positions.
300% more repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 1
0% less ownership
Funds ownership: 0% → 0% (-0%)
29% less capital invested
Capital invested by funds: $263K → $186K (-$77.2K)
42% less funds holding
Funds holding: 12 → 7 (-5)
83% less first-time investments, than exits
New positions opened: 1 | Existing positions closed: 6
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Geode Capital Management
Boston,
Massachusetts
|
+$36.4K |
| 2 |
PCMC
Private Capital Management (Colorado)
Denver,
Colorado
|
+$27.5K |
| 3 |
Jane Street
New York
|
+$17.4K |
| 4 |
SSWM
Sheets Smith Wealth Management
Winston-Salem,
North Carolina
|
+$12.9K |
| 5 |
CAPTRUST Financial Advisors
Raleigh,
North Carolina
|
+$2.43K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
-$75.3K |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$25.6K |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$24.4K |
| 4 |
VF
Virtu Financial
New York
|
-$18K |
| 5 |
TSS
Two Sigma Securities
New York
|
-$12.9K |
RNAZ Hedge Fund Activity: Q3 2024 in Review
7 of the 6,965 institutional investors tracked by Wall St. Rank reported a position in TransCode Therapeutics (RNAZ) for Q3 2024, worth a combined $186K — down 29% from $263K a quarter earlier.
Sellers outnumbered buyers: 6 funds closed out of RNAZ and 1 opened new positions — a net loss of 5 holders — while 1 trimmed existing stakes and 4 added.
The largest buyer was Geode Capital Management, adding an estimated $36.4K. The largest seller was UBS Group, exiting entirely with an estimated $75.3K sold.
- 7 institutional investors held TransCode Therapeutics (RNAZ) as of Q3 2024, down from 12 in Q2 2024.
- Funds reported $186K of TransCode Therapeutics stock for Q3 2024, down 29% quarter-over-quarter.
- 1 fund opened new TransCode Therapeutics positions in Q3 2024 and 6 closed out, a net change of -5 holders.
- The largest TransCode Therapeutics buyer in Q3 2024 was Geode Capital Management, an estimated $36.4K added.
- The largest TransCode Therapeutics seller in Q3 2024 was UBS Group, an estimated $75.3K sold.
Based on aggregated 13F filings for Q3 2024.